Dr Javier Puente (Hospital Clinico San Carlos, Madrid, Spain), Prof Jens Bedke (Klinikum Stuttgart-Katharinenhospital, Stuttgart, Germany), Prof Laurence Albiges (Institut Gustave Roussy, Villejuif, France) and Prof Viktor Grünwald (University Hospital Essen, Essen, Germany) discuss the most recent data in mRCC presented at ESMO 2025.

The discussion focuses on how these findings may reshape current treatment practice and inform future clinical decision-making.

The panel examines updates from key studies evaluating first-line, second-line and perioperative therapy, including targeted therapy combinations, novel biomarker driven regimens, immunotherapy, and how these may improve outcomes across different patient subgroups.

With insights from pivotal trials such as RAMPART, CLEAR, LenCabo, KEYMAKER-U03, OPTIC and NESCIO, the session provides a comprehensive look at the evolving therapeutic landscape and what these advances mean for personalised patient care.